April's issue of Journal of Clinical Investigation reported that UCSF’s Dr. Jeffrey Bluestone and his collaborators Matthias von Herrath and Damien Bresson at the La Jolla Institute for Allergy and Immunology and Kevan Herold of Columbia University have successfully used a new treatment approach to reverse recent onset type 1 diabetes in laboratory animals.
Therapeutic cures for diabetes may eventually range from regeneration techniques in which islets are produced endogenously, to interventions like the transplantation of islets from donors, animal sources, or engineered sources such as liver or stem cells. Regardless of the technique to replace beta cell mass, therapies won’t result in true cures without the ability to induce tolerance. In type 1 diabetes, there can be several layers of tolerance that need to be in place.
Two UCSF faculty scientists have been elected to the American Academy of Arts and Sciences, the academy announced on April 24, 2006. Jeffrey A. Bluestone, PhD, director of the UCSF Diabetes Center, and Robert W. Mahley, MD, PhD, president of the UCSF-affiliated J. David Gladstone Institutes, were among 175 new fellows elected to the academy, which includes among its members prominent scientists, scholars, artists, business leaders and public policy experts.
Christian Vaisse, MD, PhD, studies weighty matters - the genetics of obesity. He has identified a mutated gene that is responsible for extreme obesity, at least in a rare and unfortunate few. Moreover, Vaisse, an endocrinologist and associate professor with the Diabetes Center at UCSF, has recently made a patentable discovery that may one day lead to new drug treatments. So, given his success, you might expect Vaisse to be overly optimistic about genetic fixes for fat. He's not.
Using a new form of microscopy to penetrate living lymph nodes, UCSF scientists have for the first time viewed immune cells at work, helping clarify how T cells control autoimmunity.
UCSF was the fourth-largest recipient of National Institutes of Health (NIH) research dollars in 2004, receiving a total of $438.8 million from all awards in the nationally competitive process, according to new rankings released by NIH. The ranking covers research grants, awards and contracts. UCSF’s School of Dentistry, School of Nursing and School of Pharmacy each ranked first nationally for 2004, as they have in recent years.
A publication in the June issue of the scientific journal Diabetes showed that a 2-week therapy with the drug hOKT3gamma1(Ala-Ala) slows the progression of type 1 diabetes for at least two years after treatment.
For patients with diabetes, their family members and friends, nothing is more frightening than a hypoglycemic or low blood sugar episode. After the episode, many patients feel like they've been "hit by a freight train". Even though clinicians work closely with patients to reduce or eliminate these episodes, occasionally a severe hypoglycemic reaction can occur. Fortunately, thanks to researchers at the UC San Francisco VA Medical Center, a possible therapy may help prevent brain impairment
Most families affected by diabetes recognize that islet transplantation represents a very real opportunity for a cure for diabetes. Unfortunately, current experimental treatment protocols require the use of cadaveric pancreas donors. Tragically, only 300 successful islet transplants have been performed in the U.S.
Are you aware of the following shocking statistics? Nearly 100,000 American men, women and children currently await life-saving transplants, a large percentage of whom have diabetes; Approximately 18,000 Californians are waiting for an organ transplant, nearly 20% of the total number of patients waiting for a transplant -- and a second chance at life; Every 13 minutes another name is added to the national transplant waiting list; An average o
The Diabetes Center’s Dr. Ira Goldfine and his team believe they have identified one of the major proteins causing insulin resistance and type 2 diabetes. In a recent study published in the journal Diabetes, Goldfine reported that mice expressing the human version of the protein PC-1 in their liver have significantly elevated blood glucose levels and show 2-fold higher levels of insulin compared to controls.